Abstract 2278P
Background
The heterogeneity of the tumor microenvironment is a major barrier for effective cancer therapies. Similar to the immune tumor microenvironment the stromal environment, composed of cancer-associated fibroblasts (CAFs), pericytes, adipocytes and endothelial cells, is also heterogeneous. Multiple studies showed that CAFs contain heterogenous cell populations with opposing pro and anti-tumoral function. The heterogeneity of endothelial cells (ECs) is less well described largely due to the relative low frequencies in tumor tissues compare to CAFs. We set out to study the heterogeneity of the tumor microenvironment using truly single-cell spatial transcriptomic by the 10x Genomics Xenium platform.
Methods
We analyzed 20 human breast tumors by Xenium single-cell analyzes using fluorescent in situ sequencing (FISSEQ). We used the available breast panel that contains 280 genes, with 8 probes for each gene. The analysis of the data was preformed using the Seurat pipeline in R (version 4.9.9.9039).
Results
We could readily identify blood vessel structures that surrounded PECAM1/VWF positive cells. After multiple clustering we identified five types of endothelial cells with divergent gene expression profiles. We defined the following clusters of ECs: 1) Proliferating ECs, 2) CXCL12+ ECs, 3) POSTNHi/VWFHi ECs, 4) TPD52Hi ECs and POSTNLow/VWFHi ECs. The endothelial cells also showed spatial variations in distribution. Data on EC subtypes will correlation and other cell types and cell neighborhoods will be presented.
Conclusions
ECs in breast cancer tumors are highly heterogeneous and can be further classified into functionally divergent subtypes, potentially contributing to the heterogenous responses observed to treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CHUV.
Funding
CHUV.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08